Phylogica Peptide Fusion Kills Aggressive Breast Cancer Cells

31-Mar-2015 - A pilot study by Associate Professor Pilar Blancafort, a member of the Harry Perkins Institute of Medical Research, shows that Phylogica’s cell penetrating peptides (CPPs) linked with the Omomyc drug kill aggressive drug resistant breast cancer cells in vivo.Professor Blancafort also observed ...

Phylogica licenses technology to Janssen Biotech, Inc.

04-Jan-2012 - Phylogica Ltd announced a Collaboration and Option agreement with Janssen Biotech, Inc., to discover new classes of drugs derived from Phylogica’s Phylomer® peptide platform. In the initial stage of the collaboration, Phylogica will identify cell-penetrating Phylomer® peptides. Under the terms ...

Phylogica and Pepscan enter collaboration to optimise therapeutic phylomer drug candidates

11-May-2011 - Phylogica Ltd and Pepscan Therapeutics announced that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery. Under the terms of the agreement, Pepscan using its CLIPS technology will work with ...

Phylogica forms target discovery spin-off with University of Cambridge

11-Mar-2011 - Phylogica Ltd will partner with researchers from the University of Cambridge in a spin-off company to pursue a novel application of its Phylomer® peptides for discovery of disease-associated targets. The spin-off complements Phylogica’s existing business model by opening up a new market ...

Phylogica and Isogenica: Strategic alliance fast tracking screening of drug discovery targets

24-Feb-2011 - Phylogica Ltd and Isogenica Ltd have succeeded in a proof of concept project demonstrating compatibility of Isogenica’s proprietary CIS in-vitro display technology for peptide engineering and drug discovery with Phylogica’s Phylomer drug discovery platform. Phylogica scientists are now confident ...

Phylogica: New potential for treating brain injury

Novel compound protects neural tissue, reduces inflammation

22-Feb-2011 - Phylogica Ltd has successfully demonstrated preclinical proof of concept with a Phylomer peptide drug candidate for the treatment of traumatic brain injury.Using an internationally established preclinical model, a three-year collaborative study with the Australian Neuromuscular Research Institute ...

Phylogica Announces Successful Collaboration with Roche

18-Feb-2011 - Phylogica Ltd announced successful completion of the initial research objectives of its collaboration with Roche. The objective of the first stage of the research collaboration with Roche was to use Phylogica’s Phylomer drug discovery platform to identify novel cell-penetrating peptides for ...

Phylogica Signs Collaboration and Licensing Deal with Pfizer

03-Jan-2011 - Phylogica Ltd, a public Australian drug discovery company, announced that it has entered into a collaboration and licensing agreement with Pfizer to discover novel peptide-based vaccines. Phylogica will employ its proprietary Phylomer® drug discovery platform to identify Phylomer peptides ...